We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug and a reference product have the same strength. Read More
Australia’s Therapeutic Goods Administration (TGA) is asking for feedback on changes it’s considering for its generic drug market authorization process — including the potential use of foreign reference products to show bioequivalence. Read More
Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said in a report to Congress. Read More
The prescribing doctor argued that none of the additional risk information would have changed his decision to prescribe Pradaxa to the patient. Read More
In a letter to the company, Sanders claimed the drug only costs up to $6,000 to make and accused Catalyst of “corporate greed” that is “threatening access … and handing a completely unwarranted bill to American taxpayers.” Read More
The FDA released a new manual of policies and procedures (MAPP) for developing a shared system risk evaluation and mitigation strategy (REMS). Read More
A federal court this week entered a consent decree against a Pennsylvania compounder for manufacturing purportedly sterile drugs in insanitary conditions. Read More